Douglas Beall, M.D., chief of radiology services at Clinical Radiology of Oklahoma and principal investigator of the VAST study, will be presenting data from VIVEX’s 12-month study of VIA Disc® for ...
MIAMI, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced that it has treated the first patient in its Restore U.S.
Patients received a single injection of 100 mg of VIA Disc NP, a micronized cadaveric disc tissue product reconstituted with saline. Under fluoroscopic guidance, the product was delivered into ...
An injection that relieves low back pain by helping damaged spinal discs regenerate appears to have sustained benefits, new clinical trial data show. Most patients who received an injection of VIA ...
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND ...
MIAMI, June 05, 2026 (GLOBE NEWSWIRE) -- Vivex Biologics, a leader in developing and delivering innovative allografts, today announced the publication of a new real-world evidence study demonstrating ...
Analysis of 1,804 Medicare beneficiaries per group demonstrates a meaningful shift in the continuum of care following intradiscal nucleus pulposus allograft procedure MIAMI, June 05, 2026 (GLOBE ...